Conference Coverage

Warfarin dose capping avoided supratherapeutic INRs in hospitalized elderly


 

REPORTING FROM THSNA 2018


Between the pre-intervention and post-intervention periods, compliance with dose capping rose from 38.5% to 64.2% (P less than .001), the supratherapeutic INR rate dropped from 20.9% to 13.3% (P= .004), and the length of hospital stay in hours rose from a mean of 145.8 to a mean of 155.8, which was not statistically significant (P= .13).

Following the post-intervention period, the number of peak INRs in the 1 to 2 range rose by 15% and the number of peak INRs in the 2 to 3 range rose by 6%. At the same time, the number of peak INRs in the 3 to 4 range fell by 6%, the number of peak INRs in the 4 to 5 range fell by 36%, and the number of peak INRs in the 5 and greater range fell by 53%. These INR percentages represent relative increases and/or decreases.

“This was a relatively simple intervention that resulted in significant reductions in supratherapeutic INRs,” Dr. Falsetta said.

The researchers also observed that there was less IV vitamin K use after the dose capping intervention. “We can’t say for sure that this was tied to the intervention, but it was interesting, and it is something for us to take a look at, as well as roll this out in future iterations,” he said. “We are on the cusp of rolling this out at some of the tertiary sites within our health care system, and some of the community sites as well.”

Recommended Reading

Beware of polypharmacy in patients taking warfarin
MDedge Hematology and Oncology
VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
MDedge Hematology and Oncology
Many VTE patients live in fear of the next event
MDedge Hematology and Oncology
Deaths in patients on emicizumab
MDedge Hematology and Oncology
CHMP recommends approval for generic prasugrel
MDedge Hematology and Oncology
Product approved for hemophilia patients in Japan
MDedge Hematology and Oncology
CHMP recommends rejection for betrixaban
MDedge Hematology and Oncology
EHRA releases new guide for NOAC use
MDedge Hematology and Oncology
Aspirin appears comparable to rivaroxaban for VTE
MDedge Hematology and Oncology
Clopidogrel proves noninferior to Plavix
MDedge Hematology and Oncology